Tirzepatide weight loss results: what to realistically expect

Step 1: the first four weeks, adjustment before any meaningful result

The first pen you use contains 2.5mg per weekly dose. That starting strength exists to let your digestive system adapt; the nausea, fullness and changes in appetite that many people notice early on are most pronounced at this point. Weight loss during this month tends to be modest, sometimes just a few pounds. That is normal and expected.

A practical habit worth building now: take a photo of yourself in the same clothes, same spot, same lighting, at the end of week four. The scale moves slowly at first, and having a visual reference from the very beginning gives you something concrete to compare against three and six months later, more useful than the number alone. You can read more about what those early weeks look like on our four-week results page.

Nausea tends to peak in the first one to two weeks after starting or increasing a dose, then settles for most people. Eating smaller portions, avoiding fatty or very rich meals, and staying well hydrated all help the adjustment period pass more quickly.

Step 2: months one to three, the dose rises and results begin to show

Provided the 2.5mg dose was tolerated, the prescriber moves treatment to 5mg at the four-week mark. From here, weight loss typically becomes more noticeable. Appetite suppression tends to deepen, and many people find their portion sizes naturally shrink without conscious effort.

By the end of three months, trial participants at escalating doses had lost a meaningful proportion of their starting weight, though the full titration to maintenance doses takes longer. Our three-month results page covers that period in detail. It is also around this point that people often notice the first physical changes that aren't captured by the scale: clothes fitting differently, blood pressure readings improving, energy shifting.

The NICE technology appraisal for tirzepatide (TA1026) notes that if less than 5% body-weight loss has occurred after six months at the highest tolerated dose, continuing treatment should be reviewed. That threshold gives both patient and prescriber a clear, evidence-based checkpoint.

Step 3: months three to twelve, the main period of loss

This is where the SURMOUNT-1 figures are made. The 72-week trial ran participants up to 15mg, and the 20–21% average reduction at that dose accumulated steadily across this window. Weight loss in GLP-1 and dual-agonist treatment is not a straight line, it tends to follow a curve that steepens once maintenance dose is reached and then gradually flattens as the body settles toward a new set-point.

Individual variation here is real and worth acknowledging. Some participants lost considerably more than the trial average; others less. Starting BMI, metabolic health, diet quality alongside treatment, and dose tolerance all play a role. The full picture of weight loss on tirzepatide covers those variables in more depth.

The SURMOUNT-5 head-to-head trial, published in the New England Journal of Medicine in 2025, compared tirzepatide directly with semaglutide 2.4mg over 72 weeks in adults with obesity and no diabetes. Tirzepatide produced greater average weight reduction. That evidence sits behind NICE's commentary noting indirect comparisons favour tirzepatide among licensed options in this class.

Step 4: beyond twelve months, maintaining what you've lost

One finding from the SURMOUNT programme that surprised many clinicians: when participants stopped tirzepatide after the active treatment period, a substantial proportion of the weight returned within a year. This matters for how treatment is framed from the start. These medicines work while they are working, and stopping them without lifestyle changes in place tends to reverse the progress.

That is not a reason to avoid treatment. It is a reason to use the period of reduced appetite to build genuinely sustainable habits around food and movement, so that the gains are as durable as possible when treatment eventually ends or pauses. Our prescribers discuss long-term planning as part of every review, not as an afterthought.

If you're considering what treatment might look like for you personally, the Mounjaro overview sets out how tirzepatide is licensed and used in the UK, and our Mounjaro weight loss results page covers the clinical evidence alongside how people typically experience treatment in practice. For a side-by-side view of how the before-and-after data tends to look, before and after tirzepatide results walks through what that evidence shows. And if you'd like to understand the timeline in full before any numbers appear on a scale, how long Mounjaro takes to work is a useful read.

Tirzepatide is a prescription-only medicine. If you'd like to find out whether you're clinically eligible, our free consultation connects you with a GPhC-registered prescriber who reviews every case personally, the same day it's submitted. There are no subscriptions, no auto-renewals, and no obligation.